Sponsored by Shore Thing Media*

Markets have been wild lately, but I’m zeroed in on one small biotech that’s got real momentum right now. The Fed will probably stay put, but this stock’s making its own moves — here’s what I’m looking at today.

TODAY’S TOP ALERT! 

 Hoth Therapeutics (Nasdaq: HOTH)

👉  HOTH is TODAY’S #1 ALERT 👈

Top of the morning, folks,

We’re coming off of the fifth-fastest correction since WWII, with the S&P 500 pulling out of its tailspin over the past two trading days.

The Fed’s policy meeting begins today, and Jerome Powell’s comments on it tomorrow will likely determine whether that continues.

Fed funds futures have it at a 99% likelihood that rates will hold steady, and I’m throwing my hat in with them…

Chair Powell doesn’t like to defy expectations, and a rate change would certainly do that.

In the meantime, I’m sticking with my plan to identify small-stock, “tactical trade” ideas that I think have a good chance of an imminent surge.

My “tactical” idea yesterday managed to jump 13% during regular trading, and there was some incredible price action after hours, if you kept watching it…

The stock is up 11% in the pre-market as of this writing, so plenty of opportunity there to watch a solid move.

Today’s “tactical” idea is a biopharma stock that’s up 56% in 2025…

Have a look at the chart for Hoth Therapeutics, Inc. (HOTH).

The first thing I want you to notice here is the HUGE move from early March, followed by weeks of the price action building a “basing pattern.”

As you can see, HOTH is now starting to break above the upper resistance level, and that could lead to a fantastic move, possibly even re-testing the $1.50 range from earlier this month…

Also, notice that HOTH took off in January — thanks to some great news — soaring 360% in a single trading day.

The stock has pulled back a good bit since then, but it took off again in March with a 40%+ rally in two trading days.

Zooming in, the stock had some resistance around $1.13 over the past two weeks, which it pushed past yesterday with a 5.4% gain on the day.

That momentum accelerated into the close, and I think today could carry it significantly higher, as the TipRanks 1-day indicators suggest:

This stock has a history of some vertical moves, so be sure to dial into it today to see where things go.

👉  HOTH is TODAY’S #1 ALERT 👈

HOTH is a clinical-stage biopharmaceutical company based in New York that’s developing innovative treatments for unmet medical needs.

It’s especially focused on cancer-related skin toxicities, Alzheimer’s disease, and obesity.

Its lead candidate, HT-001, is a topical cream intended to treat papulopustular eruptions — a nasty skin condition caused by Epidermal Growth Factor Receptor (EGFR) inhibitors used in cancer therapy.

The company says there is “No current approved product on the market that specifically treats EGFR inhibitor cutaneous toxicities, which occur in up to 90% of patients undergoing EGFR inhibitor therapy.”

And it notes that the EGFR inhibitor skin toxicity market is predicted to grow from $52M in 2018 to $391M by the end of 2030.

HT-001 had a breakthrough last year in a first-of-its-kind human patient case…

According to HOTH, “a 59-year-old female undergoing treatment at George Washington University for metastatic breast cancer, experienced significant improvement in symptoms just one week after initiating HT-001 therapy.”

The swift resolution of her lesions meant she was able to discontinue the treatment after just seven days. And significantly, no new lesions developed in the following three weeks.

A Phase 2a clinical trial is currently underway for HT-001 at a number of sites, and the company announced promising findings at the annual meeting of the American Academy of Dermatology earlier this month.

Last week, the company revealed its plans to submit an Expanded Access application for HT-001 to allow "compassionate use” of the treatment outside of traditional clinical trials.

This move signals confidence in the drug and a push to get it to patients faster.

Beyond HT-001, HOTH is exploring broader applications…

The company partnered with OnTargetx R&D in February 2025 to advance HT-KIT, another cancer therapeutic targeting the KIT protein in mast cell-related cancers. 

In October, HOTH released “highly promising early data” from a preclinical study conducted by NC State University that “demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency across subjects.”

The company notes that HT-KIT “effectively kills human mast cells that rely on signaling through the KIT receptor to survive.”

HOTH is also advancing HT-ALZ, which it says “represents a breakthrough in Alzheimer's treatment.”

While most Alzheimer’s treatments to date focus on amyloid plaques, HT-ALZ “a novel approach … focusing on the modulation of neuroinflammation.”

To date, “Preclinical studies have shown promising results, including reduced neuroinflammation and significant improvements in cognitive functions such as memory and learning.”

Meanwhile, its preclinical work on Glial Cell Line-Derived Neurotrophic Factor (GDNF) is turning heads.

The work is the result of an “exclusive patent license agreement” with the U.S. Department of Veterans Affairs (VA) that gives HOTH exclusive rights to a patent portfolio jointly owned by the VA and Emory University.

Two weeks ago, HOTH announced preclinical findings that indicate GDNF’s potential “as a revolutionary treatment for obesity.”

The study “demonstrated that GDNF significantly reduces fat accumulation, enhances metabolism, and improves insulin sensitivity, even under high-fat diet conditions.”

Financially, HOTH is in a solid spot…

The company affirmed in January that it had “no plans for a public or private offering at this time” and that it had “a strong balance sheet that includes over $10 million in cash and no debt.”

It said its fiscal strength “positions the Company well to execute its strategic initiatives and advance its pipeline without the immediate need for additional financing.”

Analysts see significant upside for HOTH. Two analysts recently gave it an average price target of $4.50 — nearly 300% higher than yesterday’s closing price.

The other two analysts covering the stock gave it 156% and 498% upside, respectively.

I cover a lot of these biopharma stocks, and I have to say I’m very pleased with how informative the company’s website and investor presentation are, so be sure to review them as you do your own research.

And of course, always approach your trading in a responsible manner, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: HOTH is a promising biotech with potentially lucrative “shots on goal” in cancer-related skin toxicities, Alzheimer’s disease, and obesity.

Its stock has a history of vertical moves and is up 56% YTD. Its 5% gain yesterday pushed it past recent resistance, and TipRanks technicals suggest today could be a big one for the stock.

All eyes on my #1 alert for the day — HOTH — as we watch the action unfold.

To Your Success,

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull

*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty thousand dollars (cash) from Shore Thing Media for advertising Hoth Therapeutics, Inc for a one day marketing program on March 18, 2025. It might seem obvious, but while our client claims not to own any shares in Hoth Therapeutics, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Hoth Therapeutics, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.